Thursday, May 17, 2018 1:25:59 PM
The Rating
B Riley analyst Madhu Kumar initiated coverage on Tocagen with a Buy rating and a $15 price target.
The Thesis
As Kumar sees it, Toca 511/FC has potential to transform the treatment of recurrent high-grade glioma (RHGG), a brain cancer affecting about 14,000 per year with limited-efficacy treatment options.
“Overall, RHGG remains a key clinical opportunity for novel therapies that can demonstrate improved therapeutic response,” Kumar wrote in a Wednesday note.
The failures of comparable candidates for RHGG, such as Vascular Biogenics Ltd (NASDAQ: VBLT)’s VB-111, have little read-across to Toca 511/FC, he said.
Given that Phase 1 data demonstrated positive enough results to merit Breakthrough Therapy Designation and PRIME Designation, Kumar anticipates success in Tocagen’s ongoing Phase 3 TOCA 5 trial.
Interim readouts due in the second half of 2018 and first half of 2019 are seen to propel the stock, with the latter milestone driving a key inflection point. The analyst assumes a 30-percent probability of launch with a 30-percent market share but notes improvements to the estimates could support a $90 share price.
Price Action
Tocagen shares traded up 3 percent to $9.74 at time of publication.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM